Zobrazeno 1 - 10
of 64
pro vyhledávání: '"Serena Marchetti"'
Autor:
Jeroen J. M. A. Hendrikx, Frederik E. Stuurman, Ji‐Ying Song, Vincent A. deWeger, Jurjen S. Lagas, Hilde Rosing, Jos H. Beijnen, Alfred H. Schinkel, Jan H. M. Schellens, Serena Marchetti
Publikováno v:
Pharmacology Research & Perspectives, Vol 8, Iss 4, Pp n/a-n/a (2020)
Abstract Oral administration of docetaxel in combination with the CYP3A4 inhibitor ritonavir is used in clinical trials to improve oral bioavailability of docetaxel. Diarrhea was the most commonly observed and dose‐limiting toxicity. This study com
Externí odkaz:
https://doaj.org/article/312864ef1c70464298e06dea8e715675
Autor:
Roberto Mazzanti, Umberto Arena, Pietro Pantaleo, Lorenzo Antonuzzo, Greta Cipriani, Bruno Neri, Clara Giordano, Fabio Lanini, Serena Marchetti, Paolo Gentilini
Publikováno v:
Canadian Journal of Gastroenterology, Vol 18, Iss 10, Pp 611-618 (2004)
The treatment of early and intermediate stage hepatocellular carcinoma (HCC) is still debated. Surgical treatments are considered to be the only curative procedures available, and only for a minority of patients. Percutaneous ethanol injection (PEI)
Externí odkaz:
https://doaj.org/article/52e52d0b533846c9a6ecff77ec9ef7d6
Autor:
Jan de Boer, Charlotte L. Zuur, Vincent A. de Weger, Bastiaan Nuijen, Alfons J. M. Balm, Charlotte W Duinkerken, Lisette van der Molen, Serena Marchetti, Wouter A. Dreschler, Jacobus A. Burgers, Hilde Rosing, Dick Pluim, Jos H. Beijnen, Jan H.M. Schellens, Michael Hauptmann
Publikováno v:
Otology & neurotology, 42(5), 678-685. Lippincott Williams and Wilkins
Otology and Neurotology, 42(5), 678-685. LIPPINCOTT WILLIAMS & WILKINS
Otology and Neurotology, 42(5), 678-685. LIPPINCOTT WILLIAMS & WILKINS
Objectives: To determine safety, feasibility, and preliminary activity of transtympanic injection of sodium thiosulfate (STS) against cisplatin-induced hearing loss (CIHL). DESIGN Randomized controlled trial. SETTING Tertiary cancer hospital. PATIENT
Autor:
Dick Pluim, Alwin D. R. Huitema, Thomas P. C. Dorlo, Maarten van Eijk, Jos H. Beijnen, Serena Marchetti
Publikováno v:
The Pharmacogenomics Journal. 21:336-345
The anticancer drug docetaxel exhibits large interpatient pharmacokinetic and pharmacodynamic variability. In this study, we aimed to assess the functional significance of 14 polymorphisms in the CYP3A, CYP1B1, ABCB1, ABCC2, and SLCO1B3 genes for the
Autor:
Jos H. Beijnen, Alwin D. R. Huitema, Philip C. Schouten, Sabine C. Linn, Jan H.M. Schellens, Katarzyna Jóźwiak, Serena Marchetti, Gwen M. H. E. Dackus, Jill J.J. Geenen, Gabe S. Sonke, Dick Pluim
Publikováno v:
International Journal of Cancer
Preclinical studies have shown synergistic effects when combining PARP1/2 inhibitors and platinum drugs in BRCA1/2 mutated cancer cell models. After a formulation change of olaparib from capsules to tablets, we initiated a dose finding study of olapa
Publikováno v:
Clinical Pharmacology : Advances and Applications
Marit Vermunt,1 Serena Marchetti,2 Jos Beijnen1,3,4 1Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam 1066, CX, the Netherlands; 2Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam 1066,
Autor:
Thomas P. C. Dorlo, Vincent A. de Weger, Alwin D. R. Huitema, Rik E Stuurman, Serena Marchetti, Jos H. Beijnen, Bastiaan Nuijen, Huixin Yu, Jan H.M. Schellens, Julie M Janssen
Publikováno v:
Investigational New Drugs. 38:1526-1532
Introduction Oral formulations of docetaxel have successfully been developed as an alternative for intravenous administration. Co-administration with the enzyme inhibitor ritonavir boosts the docetaxel plasma exposure. In dose-escalation trials, the
Autor:
Frans L. Opdam, Robin M. J. M. van Geel, Neeltje Steeghs, Emilie M.J. van Brummelen, Alwin D. R. Huitema, Serena Marchetti, Jos H. Beijnen, Jan H.M. Schellens, Sanne Huijberts, Hilde Rosing, Kim Monkhorst, Saskia M. Pulleman, Bas Thijssen, René Bernards
Publikováno v:
Cancer Chemotherapy and Pharmacology, 85(5), 917-930. Springer Verlag
Purpose KRAS oncogene mutations cause sustained signaling through the MAPK pathway. Concurrent inhibition of MEK, EGFR, and HER2 resulted in complete inhibition of tumor growth in KRAS-mutant (KRASm) and PIK3CA wild-type tumors, in vitro and in vivo.
Autor:
Maja J.A. de Jonge, Jan H.M. Schellens, Diane A.J. van der Biessen, Andre T. Brunetto, Agnes Jager, Johann S. de Bono, Joo Ern Ang, Martijn P. Lolkema, Jacques De Greve, Hendrik-Tobias Arkenau, Ruud van der Noll, Ilian Tchakov, Jos H. Beijnen, Marja Mergui-Roelvink, Serena Marchetti
Publikováno v:
Investigational New Drugs, 38(4), 1096-1107. Kluwer Academic
Investigational New Drugs, 38. Kluwer Academic Publishers
Investigational New Drugs, 38. Kluwer Academic Publishers
Background In the first part of this extensive phase I study (NCT00516724), continuous olaparib twice daily (bid) with carboplatin and/or paclitaxel resulted in myelosuppression and dose modifications. Here, we report the safety, tolerability, and ef
Autor:
Bart A. W. Jacobs, Ellen J. B. Derissen, Thomas P.C. Dorlo, Julie M Janssen, Jos H. Beijnen, Serena Marchetti, Jeroen Roosendaal, Alwin D. R. Huitema
Publikováno v:
AAPS journal, 23(1):23. Springer New York
Capecitabine is an oral pro-drug of 5-fluorouracil. Patients with solid tumours who are treated with capecitabine may develop hand-and-foot syndrome (HFS) as side effect. This might be a result of accumulation of intracellular metabolites. We charact